Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Histologically confirmed adenocarcinoma of prostate~* Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral orchiectomy~* Progressive metastatic disease~* Adequate bone marrow, hepatic, and renal function~Exclusion Criteria:~* Known metastases in the brain~* History of other malignancy within the previous 5 years~* Known gastrointestinal disease or procedure that affects the absorption~* Not able to swallow the study drug

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ODM-201 Phase I (Type: EXPERIMENTAL): None
- ODM-201 Phase II Dose 1 (Type: EXPERIMENTAL): None
- ODM-201 Phase II Dose 2 (Type: EXPERIMENTAL): None
- ODM-201 Phase II Dose 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).